BREAKING DOWN SILOS. CONNECTING EXPERTISE. ACCELERATING PATIENT IMPACT.

Precision Medicine Europe Logo
 

Precision Medicine Europe, formerly Biomarkers, CDx & Precision Medicine Europe and NextGen Omics, Tech & Data, brings together the scientific disciplines, technologies and decision-makers advancing drug development, clinical research, diagnostics and patient care.

 

30 November - 01 December 2027
Congress Centre Basel, Basel, Switzerland


Introducing
Precision Medicine Europe

Precision medicine has changed, and so has our event in Basel.
The science behind precision medicine is converging, and so are the decisions it drives. Biomarker, omics, pathology, data and clinical teams now shape the same choices, but too often still meet apart.

That’s why, from 2027, Biomarkers, CDx & Precision Medicine Europe and NextGen Omics, Tech & Data have become Precision Medicine Europe: one event in Basel, with four interconnected programmes, built to bring Europe’s precision medicine ecosystem into one room. The specialist depth our communities value remains. What’s new is the whole ecosystem around your work, in one place. 

Hear from our CEO and Founder, Cerlin Roberts, as she explains the thinking behind the change.

What is Precision Medicine Europe?

Precision Medicine Europe is a two-day conference in Basel for the people advancing precision medicine: R&D leaders, clinicians, researchers, data scientists, investors and technology providers.

Organised by Oxford Global, it runs four interconnected programmes in biomarkers and companion diagnostics, computational pathology, multi-omics, and AI and data. Small-group formats, pre-arranged meetings and dedicated zones for AI and start-ups turn the science into decisions.

Why attend Precision Medicine Europe

  • Explore the full precision medicine ecosystem: four interconnected programmes in Biomarkers & CDx; Computational Pathology, AI & Precision Diagnostics; Multi-Omics Development & Applications; and AI, Data & Analysis, now together in one event in Basel.

  • Meet the people carrying precision medicine forward: R&D and clinical development leaders, clinicians, researchers, data scientists, investors and technology providers from across Europe’s pharma, biotech, academic and healthcare communities.

  • Work in formats built for exchange: Collaboration Hubs, closed-door panels and roundtables, plus the Hackathon, where data scientists and domain experts tackle real problems together, and the Investment Forum, where founders meet investors and pharma partners. 

  • Make the meetings that matter: shortlist the providers you want to meet, review the requests you receive, and we’ll arrange the meetings before you arrive.
PM EU About

About

Biomarkers, CDx & Precision Medicine Europe and NextGen Omics, Tech & Data have come together as Precision Medicine Europe. Find out what’s new.

Large Audience at Precision Medicine Event

Attend

Free for qualifying delegates from pharma, biotech, academia, healthcare, patient advocacy and regulatory organisations, and for investors. 

Partner Image

Partner

Meet senior decision-makers from Europe’s precision medicine community in guaranteed, pre-booked one-to-one meetings. 

PM East Program

Programme

Four interconnected programmes, keynotes, closed-door panels and roundtables, plus the Hackathon and Investment Forum. 

Onsite experiences at Precision Medicine Europe

Hackathon

Join industry, academic and healthcare experts in cross-disciplinary teams to tackle real precision medicine challenges set by industry, clinical and diagnostics leads. Work alongside expert mentors, present your solution to the judges and compete for a prize. It’s free for all non-vendor delegates.

Investment Forum

A focused deal-flow session that connects early-stage precision medicine companies with active life science investors and pharma business development teams. Hear founder pitches and expert panels on where investors see opportunity, then meet the right partners in dedicated one-on-one networking.

AI & Data Zone

A dedicated space where the companies building AI and data infrastructure for precision medicine meet the pharma, biotech and diagnostics teams who use it. See platforms in action through live demos, short technology talks and a closed-door roundtable on applying AI in precision medicine.

Start-up Zone

A dedicated space for early-stage precision medicine companies to exhibit, pitch and meet investors and pharma partners, all in two days. Eligible start-ups receive a full conference pass, a 10-minute presentation slot and exhibition space to show their technology to the teams who would use it.

Featured Speakers from Biomarkers, CDx & Precision Medicine 2026

Adisa Trnjanin
Co-Founder & Co-Head,
ZHAW Life Sciences
Aditi Deshpande
Director, Biology,
Bioage labs
Alberto Valdeolivas Urbelz
Principal Scientist,
Roche
Amela Jusic
Translational Research Lead,
Quant Biomarkers
Andrew Nelson
Senior Director,
Real Chemistry, Integrated Intelligence
Anissa Fries
Lead Scientist, Flow Cytometry,
Labcorp
Antonino Carbone
MD Pathologist,
CRO Aviano Irccs
Arijit Patra
Senior Principal Scientist,
Ucb
Bernhard Polzer
Head of Cellular and Molecular Diagnostics,
Fraunhofer Institute
Bogdan Munteanu
Lab Head Global Imaging Mass Spectrometry Biomarker Discovery Platform (DMPK),
Sanofi
Carsten Krantz
Associate Director,
Novartis
Catherine Gilbert
Field Application Scientist,
Seer
Céline Pallaud
Precision Medicine Strategy Head,
Novartis
Celine Vandamme
Director, Scientific Business Development,
CellCarta
Clare Killick-Cole
Director of Business Development,
Genomics
Daniel Truhn
Professor of AI in Medicine,
RWTH Aachen University
David Klug
Professor of Chemical Biophysics, Department of Chemistry,
Imperial College London
David Latto
Associate Product Specialist Director ,
IQVIA Laboratories
Diego Saldana Miranda
Associate Director and Senior Data Scientist,
Novartis
Enchi Liu
Vice President & Head Experimental Medicine,
Lundbeck
Eric Letouzé
Head of Single Cell,
One Biosciences
Eshita Mutt
BI,
Illumina
Eshita Mutt,
Global Head of Scientific Strategies,
StratifAI
Espen Walker
Head of Global Medical Diagnostics,
AstraZeneca
Federico Pratesi
Senior Multiomics Sales Specialist,
Illumina
Florian Langer
Sales & Applications Manager,
Histomography GmbH
Gavin Gordon
SVP, Precision Medicine & Strategic Alliances,
Singular Genomics
Georgia Cresswell
Research Services Business Development Manager,
Patholytix
Guillaume Cettou
Executive Director Diagnostics,
GSK
Heleen Verlinden
Senior Director,
Muna Therapeutics (K5)
Helene Fachim
Clinical Research Manager,
Cure Parkinson's
Inês Santarino
Business Development Manager,
Cyentia Biosource
Isabella Gashaw
Head of Experimental Sciences CRM,
Boehringer Ingelheim
Jacek Lukawy
Innovation Program Director, Translational Medicine Clinical Sciences and Innovation/NIBR,
Novartis
Jan Lukas Robertus
Honorary Associate Professor, Imperial College London and Head of Pathology Department,
Royal Brompton & Harefield NHS Foundation Trust
Janne Martikainen
Professor,
University of Eastern Finland
Jennifer Tucker
Global Head of Regulatory Affairs, Pathology Lab,
Roche Tissue Diagnostics
Jessica Apulei
Scientific Liaison Manager - EMEA,
Hologic Diagenode
JM Bokhorst
AI Research,
IndicaLabs
Johan Lundin
Research Director,
Institute for Molecular Medicine Finland (FIMM), University of Helsinki
Johan Luthman
Executive Vice President & Head R&D ,
Lundbeck
Julia Jabs
Head of Biomarker Lab Histology,
Merck Healthcare KGaA
Karthikeyan Devaraju
Sr Scientist,
Cerba Research
Kathrin Heinzmann
Senior Biomarker Scientist,
Cancer Research UK
Kathrin Schlueter
Medical Affairs Manager,
BD
Katrien Grünberg
Professor of Pathology and Head of Pathology Department,
Radboud UMC
Kedar Natarajan
Professor,
Ashoka University
Konstantinos Venetis
Head of the R&D Team,
IEO Istituto Europeo di Oncologia
Konstanty Korski
Senior MD Pathologist,
Roche
Kristin Hellman
Global Product Manager,
Olink, part of Thermo Fisher Scientific
Krzysztof Kolmus
Principal Scientist,
Ingenix
Lorcan Sherry
Chief Scientific Officer,
OracleBio
Lucas Rifkin
Executive Medical Director, Global Head of Medical & Scientific Affairs,
Labcorp
Maciej Cabanski
Vice President Biomarkers and CDx,
Monte Rosa Therapeutics
Magda Meissner
Consultant Medical Oncologist, Clinical Liquid Biopsy Lead,
Cardiff University
Maham Ansari
Senior Director, IVD Regulatory,
Precision for Medicine
Manos Karteris
Professor,
Brunel University
Marco Tecilla
Scientific Area Lead Digital Pathology,
Roche
Marie-Christine Bakker
MD-Researcher in Medical Oncology,
UMC Utrecht
Mario Kreutzfeldt
Deputy Lab Manager,  Computational Pathology and Clinical Bioinformatics Laboratory,
Geneva University Hospitals (HUG)
Martí Jimenez Mausbach
Associate Scientific Director,
Novo Nordisk
Megan O’Shaughnessy
Scientific Affairs Specialist,
ICON
Michael Rebhan
Associate Director,
Novartis
Michal Rosen Zvi
Head of AI for Drug Discovery and Translational Medicine,
Merck
Mirella El Khoury
Senior Field Application Scientist,
Quanterix
Miro Venturi
Chief Executive Officer,
DIAMANTE Healthcare Consulting
Nikolas Stathonikos
Principal Investigator AI Development & Implementation,
UMC Utrecht
Nina Linder
Professor,
Uppsala University
Nina Linder
Founder,
Foundation Medicine
Nina Skorytchenko
Chief Executive Officer,
Avenna
Oskar Smrzka
CEO/CSO,
Ablevia biotech GmbH
Özlem Akilli
Director Department of Spatial Biology and Cellular Dynamics,
TRON Translational Oncology Mainz
Paolo Paganetti
Head of Clinical & Laboratory,
Tivenix SA
Patrick Weber
Sales Solution Specialist,
Leica Microsystems, Inc.
Paul Mesange
Senior. Director, Lab Operations - Global Anatomic Pathology,
Labcorp
Paul Workman
Harrap Professor of Pharmacology and Therapeutics,
The Institute of Cancer Research, London
Peter Schüffler
Professor for Computational Pathology,
Technical University of Munich
Petra Kukkaro
Global Biomarker Diagnostic Director,
Novartis
Philip Beer
Chief Scientific Officer,
Step Pharma
Philip Zimmermann
Chief Executive Officer,
Prevision Medicine AG
Pierre Moulin
Chief Scientific Officer,
Deciphex Inc DBA Diagnexia US
Pim French
Professor Molecular Biology of Gliomas,
Erasmus MC
Priyanka Dutta Passecker
Chief Business Officer,
CellPly
Rachel Agoglia
Manager, Global Pharma Applications & Bioinformatics,
Mission Bio
Raif Yuecel
Director, Centre for Life Science Technologies,
University of Exeter
Régis Villet
VP, Commercial Strategy and Medical Innovation,
Synexa Life Sciences
Rene Kubiak
Global Head Early Development & Non-Clinical Biostatistics,
Sanofi
Road to PM Europe Light

The Road to Precision Medicine Europe

Between the events, the conversation carries on online. R&D Spotlights and CEO Thought Leadership sessions run all year, each a stop on the Road to Precision Medicine Europe.

Precision Medicine Europe: Frequently Asked Questions

When and where is Precision Medicine Europe?

30 November to 1 December 2027, at Congress Centre Basel in Basel, Switzerland.

Is Precision Medicine Europe the same event as Biomarkers Europe and NextGen Omics?
Yes. Biomarkers, CDx & Precision Medicine Europe and NextGen Omics, Tech & Data have become Precision Medicine Europe, with both communities, the same depth of content and four interconnected programmes.
Who should attend Precision Medicine Europe?
R&D leaders, clinicians, researchers, data scientists, investors and technology providers working in biomarkers, diagnostics, pathology, multi-omics, and AI and data.
What programmes run at Precision Medicine Europe?
Biomarkers & CDx; Computational Pathology, AI & Precision Diagnostics; Multi-Omics Development & Applications; and AI, Data & Analysis.
Can I meet specific people at Precision Medicine Europe?
Yes. Nearer the event, you shortlist who you would like to meet, and meetings are arranged before you arrive.

Be part of the conversations shaping
the future of medicine.

30 November - 01 December 2027
Congress Centre Basel, Basel, Switzerland